Wednesday, July 8 delivered a livelier tape, with oil spiking, biotech ripping on positive research calls, and defensive healthcare REITs quietly getting upgraded. Q2 earnings kickoff is days away, with major banks leading the calendar next week. The backdrop remains Chair Kevin Warsh's June 17 FOMC hold at 3.50%–3.75% and a CME FedWatch reading still assigning roughly an 80% probability to zero rate cuts through year-end 2026. Five names drew fresh Buy signals worth watching into Friday, July 10.
Compass Pathways (CMPS) — Evercore ISI flips bullish on the psychedelic biotech
Compass Pathways is a clinical-stage biotech developing COMP360, a psilocybin therapy for treatment-resistant depression now in Phase 3 trials. On July 8, Evercore ISI analyst Gavin Clark-Gartner upgraded the stock from In-Line to Outperform and raised his target from $8 to $21, joining a same-day maintained Buy at $21 from Stifel's Paul Matteis and a reiterated Buy at $70 from HC Wainwright's Patrick Trucchio — a three-report positive event.
Shares closed at $13.54 on July 8, up 4.20%, with a market cap of $1.30 billion. The company is unprofitable, so a trailing P/E is not meaningful — trailing EPS ran negative $1.65. The 52-week range is $3.45 to $15.40, putting shares near cycle highs. The consensus rating is Strong Buy, with 9 of 9 analysts bullish, an average target of $26.22, a median of $21, a high of $70, and a low of $17. Even the lowest target sits above the current price.
Risks: Phase 3 readout risk is binary and carries the entire thesis; cash burn on a pre-revenue balance sheet raises dilution risk; FDA labeling and REMS requirements for a controlled psychedelic could restrict launch economics; and Morgan Stanley's Judah Frommer holds a lower $17 target.
Occidental Petroleum (OXY) — Evercore ISI executes a rare two-notch upgrade
Occidental Petroleum is a major US integrated energy producer with heavy Permian Basin exposure, a growing carbon-capture business through Oxy Low Carbon Ventures, and Berkshire Hathaway as its largest holder. On July 8, Evercore ISI analyst Stephen Richardson executed a two-notch upgrade — Underperform to Outperform in a single move — and raised his target from $58 to $65. Two-notch upgrades from a firm that had been the bearish outlier are unusually convicted signals.
Shares closed at $53.69 on July 8, up 3.89%, with a market cap of $53.4 billion and a trailing P/E of 22.37. The dividend yield is roughly 2%, and the 52-week range is $38.80 to $67.45. The consensus rating is Buy, with 6 of 12 analysts bullish, an average target of $65.67, a median of $67, a high of $75 from Mizuho's Nitin Kumar, and a low of $54 held by Goldman Sachs. Evercore ISI's move now aligns with Mizuho and Wells Fargo on the bullish side.
Risks: Oil price volatility if the Israel-Iran situation cools and OPEC production discipline slips; heavy debt from the Anadarko and CrownRock acquisitions raises rate sensitivity; federal permitting uncertainty across hydrocarbon and carbon capture assets; and Goldman Sachs' Neil Mehta carries a Sell with a $54 target.
PROG Holdings (PRG) — Jefferies almost doubles its price target on the lease-to-own play
PROG Holdings provides lease-to-own solutions through partner retailers via its Progressive Leasing business, alongside the Vive Financial second-look credit product. On July 8, Jefferies analyst John Hecht upgraded the stock from Hold to Buy and raised his target from $33 to $60 — an 82% jump reflecting a significant reappraisal of the earnings trajectory. TD Cowen's Moshe Orenbuch had lifted his target to $50 from $45 while maintaining a Buy on July 7, making it a two-day positive cluster.
Shares closed at $43.08 on July 8, down 1.55%, with a market cap of $1.73 billion and a trailing P/E of 11.05 — one of the lowest multiples in fintech. Trailing EPS of $3.90 with a small dividend gives the story a value tilt. The 52-week range is $25.80 to $47.60. The consensus rating is Buy, with 3 of 5 analysts bullish, an average target of $47.30, a median of $48, a high of $60 (the new Jefferies mark), and a low of $31.
Risks: Consumer credit trends can turn quickly and lease approval rates are sensitive to macro softening; concentration with a handful of large retail partners carries counterparty risk; CFPB rulemaking on lease-to-own remains an overhang; and BTIG's Vincent Caintic maintains a Sell with a $31 target.
Sabra Health Care REIT (SBRA) — Truist elevates the skilled-nursing recovery story
Sabra Health Care REIT owns and leases skilled-nursing facilities, senior housing, and behavioral-health properties across the US and Canada, offering income investors a nearly 6% yield tied to the post-pandemic senior-care recovery. On July 8, Truist Securities analyst Michael Lewis upgraded the stock from Hold to Buy with a $22 target. The call flips the balance back bullish after a June 23 Citigroup downgrade to Neutral had left Wells Fargo's June 1 Overweight at $23 as the loudest positive voice.
Shares closed at $20.02 on July 8, down 0.18%, with a market cap of $5.05 billion and a trailing P/E of 13.09. The roughly 6% dividend yield is the standout for income-oriented readers. The 52-week range is $17.17 to $21.28. The consensus rating is Buy, with 3 of 7 analysts bullish, an average target of $21.29, a median of $22 (matching Truist), a high of $23 from Wells Fargo, and a low of $19. The story is stabilizing occupancy and improving labor availability at Sabra's operators.
Risks: Skilled-nursing operator financial health remains uneven; Medicare and Medicaid reimbursement rates could compress; higher-for-longer rates raise refinancing costs on floating-rate debt; and Citigroup's Nick Joseph moved to Neutral in June with a $19 target.
Ultrapar Participacoes (UGP) — Bank of America moves to Buy on the Brazilian energy distributor
Ultrapar Participacoes is a Brazilian holding company whose main assets are Ipiranga fuel distribution, the Ultragaz LPG distributor, and Ultracargo liquid-bulk storage. On July 8, Bank of America analyst Leonardo Marcondes upgraded the stock from Neutral to Buy and raised his target from $6.80 to $7.40 — the Street's highest mark. Marcondes had moved off a $6.30 target only nine days earlier, so the estimate trajectory is steep.
Shares closed at $5.67 on July 8, up 4.13%, with a market cap of $6.07 billion and a trailing P/E of 11.35. The roughly 4% yield and modest multiple lend this ADR defensive character. The 52-week range is $2.80 to $6.20, with shares near annual highs. The consensus rating is Buy, with 3 of 5 analysts bullish, an average target of $6.14, a median of $6, a high of $7.40 (the new BofA mark), and a low of $4.50. UBS holds a Buy at $7.20.
Risks: Brazilian real depreciation compresses USD returns even when the underlying business performs; Petrobras fuel-pricing shifts can whipsaw Ipiranga margins; regulatory intervention in Brazilian fuels remains an overhang; and Goldman Sachs's Bruno Amorim carries a low $4.50 target.
Found this helpful? Share it with others.